Gallium-68 PSMA-11 PET Imaging in Patients With Biochemical Recurrence

Inclusion Criteria

- Histopathologically proven prostate adenocarcinoma.

- Rising PSA (at least two consecutive rising PSAs) after definitive therapy with
prostatectomy or radiation therapy (external beam or brachytherapy).

- Post radical prostatectomy (RP) - AUA recommendation for biochemical recurrence
after radical prostatectomy

- PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after RP.

- Post-radiation therapy -ASTRO-Phoenix consensus definition of biochemical
recurrence after radiation therapy

- Nadir + greater than or equal to 2 ng/mL rise in PSA

- Karnofsky performance status of > 50 (or ECOG/WHO equivalent).

- Age > 18.

- Ability to understand a written informed consent document, and the willingness to sign
it.

Exclusion Criteria

- Unable to lie flat, still or tolerate a PET scan.

- Concomitant investigational therapy.

- Patient undergoing active treatment for non-prostate malignancy, other than skin basal
cell or cutaneous superficial squamous cell carcinoma that has not metastasized and
superficial bladder cancer.

- Contraindication to furosemide administration including prior allergy or adverse
reaction to furosemide or sulfa drugs. (Note: This exclusion criteria can be removed
if Furosemide is omitted as part of the PET imaging protocol if a second-generation
scatter correction is available for the used PET device).